000144418 001__ 144418
000144418 005__ 20240229123018.0
000144418 0247_ $$2doi$$a10.1002/ijc.32576
000144418 0247_ $$2pmid$$apmid:31319002
000144418 0247_ $$2ISSN$$a0020-7136
000144418 0247_ $$2ISSN$$a1097-0215
000144418 0247_ $$2altmetric$$aaltmetric:63771407
000144418 037__ $$aDKFZ-2019-01871
000144418 041__ $$aeng
000144418 082__ $$a610
000144418 1001_ $$00000-0001-9219-4436$$aChristakoudi, Sofia$$b0
000144418 245__ $$aBlood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition.
000144418 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000144418 3367_ $$2DRIVER$$aarticle
000144418 3367_ $$2DataCite$$aOutput Types/Journal article
000144418 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1587465734_19055
000144418 3367_ $$2BibTeX$$aARTICLE
000144418 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144418 3367_ $$00$$2EndNote$$aJournal Article
000144418 500__ $$a2020 May 15;146(10):2680-2693
000144418 520__ $$aSeveral studies have reported associations of hypertension with cancer, but not all results were conclusive. We examined the association of systolic (SBP) and diastolic (DBP) blood pressure with the development of incident cancer at all anatomical sites in the European Prospective Investigation into Cancer and Nutrition (EPIC). Hazard ratios (HR) (95% confidence intervals) were estimated using multivariable Cox proportional hazards models, stratified by EPIC-participating centre and age at recruitment, and adjusted for sex, education, smoking, body mass index, physical activity, diabetes and dietary (in women also reproductive) factors. The study included 307,318 men and women, with an average follow-up of 13.7 (standard deviation 4.4) years and 39,298 incident cancers. We confirmed the expected positive association with renal cell carcinoma: HR=1.12 (1.08-1.17) per 10mmHg higher SBP and HR=1.23 (1.14-1.32) for DBP. We additionally found positive associations for esophageal squamous cell carcinoma (SCC): HR=1.16 (1.07-1.26) (SBP), HR=1.31 (1.13-1.51) (DBP), weaker for head and neck cancers: HR=1.08 (1.04-1.12) (SBP), HR=1.09 (1.01-1.17) (DBP) and, similarly, for skin SCC, colon cancer, post-menopausal breast cancer and uterine adenocarcinoma (AC), but not for esophageal AC, lung SCC, lung AC, or uterine endometroid cancer. We observed weak inverse associations of SBP with cervical SCC: HR=0.91 (0.82-1.00) and lymphomas: HR=0.97 (0.93-1.00). There were no consistent associations with cancers in other locations. Our results are largely compatible with published studies and support weak associations of blood pressure with cancers in specific locations and morphologies. This article is protected by copyright. All rights reserved.
000144418 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144418 588__ $$aDataset connected to CrossRef, PubMed,
000144418 7001_ $$aKakourou, Artemisia$$b1
000144418 7001_ $$aMarkozannes, Georgios$$b2
000144418 7001_ $$aTzoulaki, Ioanna$$b3
000144418 7001_ $$aWeiderpass, Elisabete$$b4
000144418 7001_ $$aBrennan, Paul$$b5
000144418 7001_ $$aGunter, Marc$$b6
000144418 7001_ $$aDahm, Christina C$$b7
000144418 7001_ $$aOvervad, Kim$$b8
000144418 7001_ $$aOlsen, Anja$$b9
000144418 7001_ $$aTjønneland, Anne$$b10
000144418 7001_ $$00000-0002-5956-5693$$aBoutron-Ruault, Marie-Christine$$b11
000144418 7001_ $$aMadika, Anne-Laure$$b12
000144418 7001_ $$aSeveri, Gianluca$$b13
000144418 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b14$$udkfz
000144418 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b15$$udkfz
000144418 7001_ $$aBergmann, Manuela M$$b16
000144418 7001_ $$aBoeing, Heiner$$b17
000144418 7001_ $$aKarakatsani, Anna$$b18
000144418 7001_ $$aMartimianaki, Georgia$$b19
000144418 7001_ $$aThriskos, Paschalis$$b20
000144418 7001_ $$aMasala, Giovanna$$b21
000144418 7001_ $$00000-0001-5201-172X$$aSieri, Sabina$$b22
000144418 7001_ $$aPanico, Salvatore$$b23
000144418 7001_ $$aTumino, Rosario$$b24
000144418 7001_ $$00000-0001-8749-9737$$aRicceri, Fulvio$$b25
000144418 7001_ $$aAgudo, Antonio$$b26
000144418 7001_ $$aRedondo-Sánchez, Daniel$$b27
000144418 7001_ $$aColorado-Yohar, Sandra M$$b28
000144418 7001_ $$aMokoroa, Olatz$$b29
000144418 7001_ $$aMelander, Olle$$b30
000144418 7001_ $$aStocks, Tanja$$b31
000144418 7001_ $$00000-0001-6808-4405$$aHäggström, Christel$$b32
000144418 7001_ $$aHarlid, Sophia$$b33
000144418 7001_ $$aBueno-de-Mesquita, Bas$$b34
000144418 7001_ $$avan Gils, Carla H$$b35
000144418 7001_ $$aVermeulen, Roel C H$$b36
000144418 7001_ $$aKhaw, Kay-Tee$$b37
000144418 7001_ $$aWareham, Nicholas J$$b38
000144418 7001_ $$aTong, Tammy Y N$$b39
000144418 7001_ $$aFreisling, Heinz$$b40
000144418 7001_ $$aJohansson, Mattias$$b41
000144418 7001_ $$aLennon, Hannah$$b42
000144418 7001_ $$aAune, Dagfinn$$b43
000144418 7001_ $$aRiboli, Elio$$b44
000144418 7001_ $$aTrichopoulos, Dimitrios$$b45
000144418 7001_ $$aTrichopoulou, Antonia$$b46
000144418 7001_ $$aTsilidis, Konstantinos K$$b47
000144418 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32576$$gp. ijc.32576$$n10$$p2680-2693$$tInternational journal of cancer$$v146$$x1097-0215$$y2020
000144418 909CO $$ooai:inrepo02.dkfz.de:144418$$pVDB
000144418 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000144418 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000144418 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144418 9141_ $$y2020
000144418 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144418 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144418 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144418 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144418 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000144418 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144418 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144418 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144418 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144418 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144418 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144418 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000144418 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000144418 980__ $$ajournal
000144418 980__ $$aVDB
000144418 980__ $$aI:(DE-He78)C020-20160331
000144418 980__ $$aUNRESTRICTED